Fischer Medical Ventures Limited appointed David Yeow as an additional independent director effective September 3, 2026. The company also announced September 22, 2026, as the record date for its 33rd Annual General Meeting and dividend entitlement.

The Board of Directors approved these governance updates in a meeting held on September 3, 2026. The appointment was made pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The record date intimation was issued under Regulation 42 of the same regulations.

Director Appointment Details

Mr. Yeow joins the board for a first term of five consecutive years, subject to shareholder approval. He is not liable to retire by rotation. The Singapore-based engineer brings over three decades of experience in manufacturing, quality systems, and global supply chain management.

He holds a Diplôme d'Ingénieur in Electronic Engineering from the École Nationale Supérieure d'Électronique et de Radioélectricité de Bordeaux and is a GE-certified Six Sigma Blackbelt. Previously, he held senior leadership roles at GE Plastics, Lanxess, and NTUitive. He currently serves as Principal at Hunniwell Lake Ventures, a medical device venture capital firm.

Audit Committee Reconstitution

Following the new appointment, the Board reconstituted the Audit Committee. The committee now comprises seven members, including four independent directors, one executive director, and one whole-time director.

AGM Scheduling and Record Dates

The company will hold its 33rd Annual General Meeting on Tuesday, September 29, 2026, at 11:00 am through video conferencing or other audio-visual means. M/s Nuren Lodaya & Associates Practising Company Secretary has been appointed as the scrutinizer for the e-voting process.

The Register of Members and Share Transfer Books will remain closed from September 23, 2026, to September 29, 2026, inclusive. This closure facilitates the AGM proceedings.

Tuesday, September 22, 2026, is the cut-off date for determining voting rights for e-voting on resolutions listed in the AGM notice and for dividend entitlement. The cut-off date for determining shareholders entitled to receive the dispatch of the AGM notice was September 4, 2026.

The e-voting period commences on Saturday, September 26, 2026, at 9:00 am and ends on Monday, September 28, 2026, at 5:00 pm. The Annual Report along with the notice of AGM has been dispatched to all eligible shareholders on September 7, 2026, through email and a letter containing the web link to those shareholders whose email ID is not registered with the Company or the RTA.

Fischer Medical Ventures is pursuing next-generation 3T imaging development and expanding its healthcare footprint into Southeast Asia, marking a dual-front strategic push in medical technology.

Strategic focus areas

The company's initiatives span two key areas: advancing imaging technology and entering new geographic markets. The following table outlines the core strategic directions disclosed:

Next-generation 3T imaging development

Fischer Medical Ventures is engaged in the development of next-generation 3T imaging solutions. 3T imaging refers to 3 Tesla magnetic resonance imaging, a high-field MRI technology used in advanced diagnostic applications. The company's focus on this segment positions it within the high-end diagnostic equipment space.

Southeast Asian healthcare expansion

Alongside its technology development efforts, Fischer Medical Ventures is directing attention toward healthcare expansion in Southeast Asia. This geographic push reflects the company's intent to establish or grow its presence in regional healthcare markets beyond its existing operational base.

Key highlights

• Next-generation 3T imaging technology under development
• Healthcare market expansion targeted in Southeast Asia
• Dual-front strategy covering both technology and geography